New Drug Application News and Research

RSS
Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

FDA accepts Tris Pharma's Dyanavel XR NDA for review

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Johns Hopkins researchers identify new therapy to treat lung cancer

Johns Hopkins researchers identify new therapy to treat lung cancer

Two-drug combination improves lung function in some cystic fibrosis patients

Two-drug combination improves lung function in some cystic fibrosis patients

Egalet announces business highlights, financial results for first quarter 2015

Egalet announces business highlights, financial results for first quarter 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan releases generic version of Seasonale Tablets in the U.S.

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO